When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 16 Mar 2025
Last updated: 25 Jun 2024

Summary

Definition

History and exam

Key diagnostic factors

  • hallucinations
  • delusions
  • passivity phenomena
  • negative symptoms
  • disorganised thinking (formal thought disorder)
  • catatonia

Other diagnostic factors

  • agitation or distress
  • suicidal thoughts
  • altered cognition
  • loss of insight

Risk factors

  • family history of schizophrenia
  • increasing paternal age
  • obstetric complications
  • cannabis use
  • low IQ
  • motor dysfunction
  • psychological stress
  • childhood adversity
  • migrant status

Diagnostic investigations

Treatment algorithm

Contributors

Expert advisers

Stephen Lawrie, MB ChB, MRCPsych, MPhil, MD (Hons), FRCPsych, Hon.FRCP(Edin), FRSE

Professor of Psychiatry and Neuroimaging

University of Edinburgh

Honorary Consultant Psychiatrist

NHS Lothian

Royal Edinburgh Hospital

Edinburgh

UK

Disclosures

SL declares that he has no competing interests.

Acknowledgements

BMJ Best Practice would like to gratefully acknowledge the previous team of expert contributors, whose work is retained in parts of the content:

Fiona Gaughran, MB BCh, BAO (Hons), MRCPI, MD NUI, FRCP, FRCPI, FRCP Edin, FRCPsych, FHEA

Lead Consultant Psychiatrist

National Psychosis Service

Director of Research and Development

South London and Maudsley NHS Foundation Trust

Reader in Psychopharmacology and Physical Health

Institute of Psychiatry, Psychology and Neuroscience

Kings College London

UK

Toby Pillinger, MA(Oxon), BM, BCh, MRCP, PhD

Academic Clinical Lecturer

Institute of Psychiatry, Psychology and Neuroscience

King's College London

UK

Adrian Preda, MD

Professor of Clinical Psychiatry

Department of Psychiatry and Human Behavior

University of California, Irvine School of Medicine

Irvine

CA

Robert G. Bota, MD

Health Sciences Clinical Professor of Psychiatry

University of California

Irvine

CA

Disclosures

​FG has received support or honoraria for CME, advisory work, and lectures from Lundbeck, Otsuka, and Sunovion; collaborated with a research group supported by NHS Innovations and Janssen; has a family member with professional links to Lilly and GSK, including shares; and is in part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London and the South London Collaboration for Leadership in Applied Health Research & Care Funding scheme, and by the Maudsley Charity and the Stanley Medical Research Institute. ​​​​TP has received honoraria for contributing to speaker meetings organised by Sunovion, Lundbeck, and Otsuka. AP declares that he has no competing interests. RGB declares that he has no competing interests.

Peer reviewers

Jonathan Mitchell, MBChB, MRCPsych

Consultant Psychiatrist

Sheffield Health and Social Care NHS Foundation Trust

Sheffield

UK

Disclosures

JM has been involved in production of National Institute for Health and Care Excellence (NICE) guidance on this topic and is a member of the expert advisors panel for the NICE centre for guidelines. He was involved in an NIHR-funded research project on the physical health of people with schizophrenia.

Use of this content is subject to our disclaimer